Search results for "Cer"

showing 10 items of 24496 documents

Krapina atlases suggest a high prevalence of anatomical variations in the first cervical vertebra of Neanderthals

2020

The first cervical vertebra, atlas, and its anatomical variants have been widely studied in Homo sapiens. However, in Neanderthals, the presence of anatomical variants of the atlas has been very little studied until very recently. Only the Neanderthal group from the El Sidrón site (Spain) has been analysed with regard to the anatomical variants of the atlas. A high prevalence of anatomical variants has been described in this sample, which points to low genetic diversity in this Neanderthal group. Even so, the high prevalence of anatomical variations detected in El Sidrón Neanderthal atlases needs to be confirmed by analysing more Neanderthal remains. In this context, we analysed the possibl…

0301 basic medicineAnatomical variantsHistologyNeanderthaleducationBiologyanatomical variants ; atlas ; Krapina ; NeanderthalNeanderthal03 medical and health sciences0302 clinical medicineAltlasbiology.animalCorrespondenceForamenAnimalsCervical AtlasAtlas archMolecular BiologyEcology Evolution Behavior and SystematicsNeanderthalsBiological Variation IndividualHigh prevalenceFossilsKrapinaCell BiologyAnatomyFirst cervical vertebraBiological EvolutionOriginal Papers030104 developmental biologyHomo sapiensAnatomy030217 neurology & neurosurgeryDevelopmental BiologyJournal of Anatomy
researchProduct

Middle Pleistocene protein sequences from the rhinoceros genus Stephanorhinus and the phylogeny of extant and extinct Middle/Late Pleistocene Rhinoce…

2017

BackgroundAncient protein sequences are increasingly used to elucidate the phylogenetic relationships between extinct and extant mammalian taxa. Here, we apply these recent developments to Middle Pleistocene bone specimens of the rhinoceros genusStephanorhinus. No biomolecular sequence data is currently available for this genus, leaving phylogenetic hypotheses on its evolutionary relationships to extant and extinct rhinoceroses untested. Furthermore, recent phylogenies based on Rhinocerotidae (partial or complete) mitochondrial DNA sequences differ in the placement of the Sumatran rhinoceros (Dicerorhinus sumatrensis). Therefore, studies utilising ancient protein sequences from Middle Pleis…

0301 basic medicineAncient proteinsBioinformaticsZoologylcsh:MedicineRhinocerosProtein degradationBiologyRhinocerotidaeGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesWoolly rhinocerosbiology.animalMolecular BiologyStephanorhinusStephanorhinusGeneral Neurosciencelcsh:RPaleontologyPalaeoproteomicsGeneral MedicineCoelodontabiology.organism_classificationDicerorhinus sumatrensisEquusEvolutionary StudiesPhylogenetics030104 developmental biologyEvolutionary biologyEquidaeGeneral Agricultural and Biological Sciences
researchProduct

Effects of oleuropein on tumor cell growth and bone remodelling: Potential clinical implications for the prevention and treatment of malignant bone d…

2020

Oleuropein (Ole) is the main bioactive phenolic compound present in olive leaves, fruits and olive oil. This molecule has been shown to exert beneficial effects on several human pathological conditions. In particular, recent preclinical and observational studies have provided evidence that Ole exhibits chemo-preventive effects on different types of human tumors. Studies undertaken to elucidate the specific mechanisms underlying these effects have shown that this molecule may thwart several key steps of malignant progression, including tumor cell proliferation, survival, angiogenesis, invasion and metastasis, by modulating the expression and activity of several growth factors, cytokines, adh…

0301 basic medicineAngiogenesisIridoid GlucosidesMetastasiChemoprevention030226 pharmacology & pharmacyGeneral Biochemistry Genetics and Molecular BiologyMetastasisBone remodeling03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOleuropeinmedicineAnimalsHumansIridoidsGeneral Pharmacology Toxicology and PharmaceuticsBoneCancerCell ProliferationOleuropeinbusiness.industryCell adhesion moleculePolyphenolsGeneral Medicinemedicine.diseaseTumor progression030104 developmental biologyCellular MicroenvironmentchemistryTumor progressionBone metastasiCancer cellSettore BIO/14 - FarmacologiaDisease ProgressionCancer researchBone RemodelingBone DiseasesbusinessHoming (hematopoietic)Life Sciences
researchProduct

Expression Profile of VEGF-C, VEGF-D, and VEGFR-3 in Different Grades of Endometrial Cancer

2019

Background:Vascular endothelial growth factor (VEGF)-C, -D, and VEGF receptor-3 are proteins characterized as crucial for tumor lymphangiogenesis. It is accompanied by angiogenesis during wound healing, but also in the neoplastic process. The research studies have shown that the lymphatic system plays a key role in the progression of carcinogenesis.Objective:The aim of this study was to evaluate changes in the expression of VEGF-C, VEGF-D and VEGFR-3 in different grades of endometrial cancer (G1-G3).Methods:The study included 45 patients diagnosed with endometrial cancer (G1=17; G2=15; G3=13) and 15 patients without neoplastic changes. The expression of VEGF-C, VEGF-D, and VEGFR-3 was asses…

0301 basic medicineAngiogenesisVascular Endothelial Growth Factor CVascular Endothelial Growth Factor DVEGF-CPharmaceutical ScienceVEGF-Dmedicine.disease_causeMetastasisTranscriptome03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineHumansANOVANeovascularization Pathologicbusiness.industryEndometrial cancerCancerVascular Endothelial Growth Factor Receptor-3medicine.diseaseImmunohistochemistryEndometrial NeoplasmsLymphangiogenesisVEGFR-3lymphangiogenesisVascular endothelial growth factor030104 developmental biologychemistry030220 oncology & carcinogenesisendometrial cancerCancer researchFemaleNeoplasm GradingCarcinogenesisbusinessBiotechnologyCurrent Pharmaceutical Biotechnology
researchProduct

Chemoprevention and therapeutic role of essential oils and phenolic compounds: Modeling tumor microenvironment in glioblastoma

2021

Glioblastoma (GBM) is the most common primary tumor of the central nervous system. Current treatments available for GBM entails surgical resection followed by temozolomide chemotherapy and/or radiotherapy, which are associated with multidrug resistance and severe side effects. While this treatment could yield good results, in almost all cases, patients suffer from relapse, which leads to reduced survival rates. Thus, therapeutic approaches with improved efficiency and reduced off-target risks are needed to overcome these problems. Regarding this, natural products appear as a safe and attractive strategy as chemotherapeutic agents or adjuvants in the treatment of GBM. Besides the increasing …

0301 basic medicineAngiogenesismedicine.medical_treatmentAntineoplastic AgentsMetastasis03 medical and health sciences0302 clinical medicinePhenolsOils VolatileTumor MicroenvironmentAnimalsHumansMedicinePharmacologyBiological ProductsChemotherapyTumor microenvironmentTemozolomideBrain Neoplasmsbusiness.industrymedicine.diseasePrimary tumorRadiation therapy030104 developmental biology030220 oncology & carcinogenesisCancer researchNeoplasm Recurrence LocalStem cellGlioblastomabusinessmedicine.drugPharmacological Research
researchProduct

The Role of Osteoprotegerin and Its Ligands in Vascular Function

2019

International audience; The superfamily of tumor necrosis factor (TNF) receptors includes osteoprotegerin (OPG) and its ligands, which are receptor activators of nuclear factor kappa-B ligand (RANKL) and TNF-related apoptosis-inducing ligand (TRAIL). The OPG/RANKL/RANK system plays an active role in pathological angiogenesis and inflammation as well as cell survival. It has been demonstrated that there is crosstalk between endothelial cells and osteoblasts during osteogenesis, thus establishing a connection between angiogenesis and osteogenesis. This OPG/RANKL/RANK/TRAIL system acts on specific cell surface receptors, which are then able to transmit their signals to other intracellular comp…

0301 basic medicineAngiogenesismedicine.medical_treatmentReview030204 cardiovascular system & hematologyLigandslcsh:ChemistryTNF-Related Apoptosis-Inducing Ligand0302 clinical medicineReceptorlcsh:QH301-705.5Cellular SenescenceSpectroscopyReceptor Activator of Nuclear Factor-kappa BbiologyChemistryvascular diseaseGeneral MedicineComputer Science ApplicationsProtein Transportmedicine.anatomical_structureCytokineRANKLTumor necrosis factor alphaDisease Susceptibilitymedicine.symptomProtein BindingSignal Transductionmusculoskeletal diseasesProteasome Endopeptidase ComplexEndotheliumendotheliumNeovascularization PhysiologicInflammationCatalysisInorganic ChemistryStructure-Activity Relationship03 medical and health sciencesOsteoprotegerin[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicineAnimalsHumansPhysical and Theoretical ChemistryMolecular BiologyMyocardiumRANK LigandOrganic ChemistryEndothelial Cells030104 developmental biologylcsh:Biology (General)lcsh:QD1-999osteoprotegerinOPG/RANKL/RANKCancer researchbiology.proteinBlood VesselsBiomarkers
researchProduct

Thymoquinone as a Potential Adjuvant Therapy for Cancer Treatment: Evidence from Preclinical Studies

2017

Thymoquinone (TQ), the main bioactive component of Nigella sativa, has been found to exhibit anticancer effects in numerous preclinical studies. Due to its multitargeting nature, TQ interferes in a wide range of tumorigenic processes and counteracts carcinogenesis, malignant growth, invasion, migration, and angiogenesis. Moreover, TQ can specifically sensitize tumor cells toward conventional cancer treatments (e.g., radiotherapy, chemotherapy, and immunotherapy) and simultaneously minimize therapy-associated toxic effects in normal cells. In this review, we summarized the adjuvant potential of TQ as observed in various in vitro and in vivo animal models and discussed the pharmacological pro…

0301 basic medicineAngiogenesismedicine.medical_treatmentthymoquinoneReviewPharmacologycancer treatment03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAdjuvant therapyMedicinePharmacology (medical)preclinical studiesThymoquinonePharmacologyChemotherapybusiness.industrylcsh:RM1-950Canceradjuvant therapyImmunotherapymedicine.diseaseRadiation therapylcsh:Therapeutics. Pharmacology030104 developmental biologychemistry030220 oncology & carcinogenesisCancer researchbusinessAdjuvantFrontiers in Pharmacology
researchProduct

Cardiotoxic Effects of Anti-VEGFR Tyrosine Kinase Inhibitors

2016

Angiogenesis is a key moment in tumor development and proliferation. Until recently oncologists did not know the mechanisms that were behind this phenomenon, but following the discoveries of Folkman and coworkers, they have gradually created and developed a series of drugs that act against angiogenesis by interacting with molecules belonging to the vascular endothelial growth factor (VEGFs) class and its receptors (VEGFRs) giving rise to anticancer effects. Tyrosine kinase inhibitors (TKIs) are a major class of these new anticancer agents, demonstrating high antitumor activity in a variety of "orphan" neoplasms (such as hepatocellular carcinoma, kidney cancer, sarcomas, etc.). The mechanism…

0301 basic medicineAngiogenesis; Cardio-oncology; Cardiotoxicity; Tyrosine kinase inhibitors; VEGF; VEGF pathway; Medicine (all)Settore MED/06 - Oncologia MedicaAngiogenesisTyrosine kinase inhibitorPharmacology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineVEGF pathwaymedicineReceptorCardiotoxicitybusiness.industryMedicine (all)medicine.diseaseVEGFCardiotoxicityVascular endothelial growth factorAngiogenesiCardio-oncology030104 developmental biologyMechanism of actionchemistry030220 oncology & carcinogenesisHepatocellular carcinomamedicine.symptombusinessKidney cancerTyrosine kinase
researchProduct

Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia.

2018

Background Anthracyclines in combination with cytarabine have been the standard therapy for acute myeloid leukemia (AML) for decades with high efficacy. However, the majority of patients will show initial resistance or will relapse after initial complete remission. Genetic variability in genes involved in anthracyclines metabolic pathway could be one of the causes of the interindividual differences in clinical outcomes. Methods A systematic review of published studies in AML cohorts was carried out in order to analyze the influence of polymorphisms in genes of anthracycline metabolism on efficacy and toxicity. Results Polymorphisms in the main enzymes of anthracyclines metabolism (CBR, AKR,…

0301 basic medicineAnthracyclinemedicine.medical_treatmentClinical BiochemistryEfficacy03 medical and health sciences0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineIdarubicinHumansAnthracyclinesPharmacologyCardiotoxicityChemotherapyPolymorphism Geneticbusiness.industryCytarabineMyeloid leukemiaLeukemia Myeloid Acute030104 developmental biologyPharmacogenetics030220 oncology & carcinogenesisCytarabineCancer researchbusinessPharmacogeneticsmedicine.drugCurrent drug metabolism
researchProduct

Abstract 882: The anti-claudin 6 antibody, IMAB027, induces antibody-dependent cellular and complement-dependent cytotoxicity in claudin 6-expressing…

2018

Abstract Background Claudin 6 (CLDN6) is a tight junction membrane protein whose expression in normal tissue is confined to embryonic cells, but aberrantly expressed in various human cancer types, including some with a high medical need (eg, ovarian and uterine cancers). This tumor-specific expression in adult organs makes CLDN6 an attractive drug target; as such, IMAB027, an anti-CLDN6 monoclonal antibody (mAb), was developed. This report describes the preclinical characteristics of IMAB027. Methods IMAB027 was generated by hybridoma technology; the discovery process was set up so that mAbs that were good binders as well as inducers of the immune effector mechanisms of antibody-dependent c…

0301 basic medicineAntibody-dependent cell-mediated cytotoxicityCancer ResearchbiologyChemistryCancermedicine.diseaseComplement-dependent cytotoxicity03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyCell cultureIn vivo030220 oncology & carcinogenesisCancer cellCancer researchmedicinebiology.proteinAntibodyCytotoxicityCancer Research
researchProduct